Evidence map›Paper›PMID 30829289›Full record

ArticleAsian journal of andrology

The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction.

Min Chul Cho, Junghoon Lee, Juhyun Park, Sohee Oh, Ji Sun Chai, Hwancheol Son, Jae-Seung Paick, Soo Woong Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Min Chul ChoDepartment of Urology, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul 07061, Korea.
Junghoon LeeDepartment of Urology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea.
Juhyun ParkDepartment of Urology, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul 07061, Korea.
Sohee OhDepartment of Biostatistics, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul 07061, Korea.
Ji Sun ChaiDepartment of Urology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea.
Hwancheol SonDepartment of Urology, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul 07061, Korea.
Jae-Seung PaickDepartment of Urology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea.
Soo Woong KimDepartment of Urology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea.
Seoul National University Hospital · KRSeoul National University · KRSNUH SMG-SNU Boramae Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to determine whether combination of LIM-kinase 2 inhibitor (LIMK2i) and phosphodiesterase type-5 inhibitor (PDE5i) could restore erectile function through suppressing cavernous fibrosis and improving cavernous apoptosis in a rat model of cavernous nerve crush injury (CNCI). Seventy 12-week-old Sprague-Dawley rats were equally distributed into five groups as follows: (1) sham surgery (Group S), (2) CNCI (Group I), (3) CNCI treated with daily intraperitoneal administration of 10.0 mg kg

Indexed as

AnimalsApoptosisArterial PressureBenzenesulfonamidesElectric StimulationErectile DysfunctionLim KinasesMaleNerve CrushNitric Oxide Synthase Type IIIPenisPeripheral Nerve InjuriesPhosphodiesterase 5 InhibitorsPhosphorylationPyrimidinesRatsBenzenesulfonamidesLimk2 protein, ratLim KinasesNitric Oxide Synthase Type IIINos3 protein, ratPhosphodiesterase 5 InhibitorsPyrimidinesSulfonamidesudenafilapoptosiserectile dysfunctionfibrosisLIM kinasephosphodiesterase

Identifiers

PMID30829289
PMCPMC6732899
OpenAlexW2916951906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.